<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01741987</url>
  </required_header>
  <id_info>
    <org_study_id>1346/08</org_study_id>
    <nct_id>NCT01741987</nct_id>
  </id_info>
  <brief_title>Osmoprotective Containing Lubricants in Dysfunctional Tear Syndrome and Post Refractive Surgery Patients</brief_title>
  <official_title>An Effectiveness of Osmoprotective Containing Lubricants in Dysfunctional Tear Syndrome (DTS) and Post Refractive Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of São Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to determine the effectiveness of an eyewash osmoprotective
      lubricant comparing to castor oil containing and non-osmoprotective lubricants in different
      types of DTS and post refractive surgery patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patients satisfaction with osmoprotective lubricant on different types DTS.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Our purpose is to determine the differential effects of Optive® castor oil Endura ® on different types DTS.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician satisfaction with Optive®</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Our purpose is to determine the differential effects of Optive® vs. FreshTears ® on post refractive surgery patients.</measure>
    <time_frame>3 monthas</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change from baseline in Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>3 moths</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change from baseline in tear break up time (BUT)</measure>
    <time_frame>3 mothas</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change from baseline in lissamine green staining</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change form baseline in impression cytology</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>change from baseline in tear osmolarity</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Dry Eye</condition>
  <condition>Ametropia</condition>
  <arm_group>
    <arm_group_label>optive® eye drop</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>fresh tears ® eye drop</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optive ®</intervention_name>
    <description>instilation of 1 drop each eye 4 times per day</description>
    <arm_group_label>fresh tears ® eye drop</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fresh Tears ®</intervention_name>
    <description>instilation of eye drop 4 times a day (qid)</description>
    <arm_group_label>optive® eye drop</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients willing and able to comply with the protocol who are not planning
             changes in diet, topical or systemic drugs during the course of study.

          2. DTS all the patients will be diagnosed for mild to moderate evaporative dry eye as
             defined by following criteria that will be given by Outcome measurements:

             2.1. Break up time. 2.2. Lissamine green staining. 2.3. OSDI and Patient
             Symptomatology Questionnaire.

          3. The patients, whose are going to be submitted for refractive surgery.

        Exclusion Criteria:

          1. Any patient with punctual occlusion or punctual plugs.

          2. Patients with active ocular infection or inflammatory disease, history of herpetic
             keratitis, history of retinal detachment, concurrent contact lens use during trial
             period,

          3. Patients with glaucoma, anterior membrane dystrophy, active trichiasis or any eyelid
             globe malposition abnormality.

          4. Patients with Epiphora.

          5. Patients must not have participated in any investigational therapeutic drug or device
             trial within the 30 days prior to their start date for this trial.

          6. Any patient suffering from organic brain syndromes or major psychiatric disorder that
             would interfere with compliance or subjective reporting will be discouraged from
             participating in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rossen M Hazarbassanov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophtahlmology, UNIFESP&amp; EPM, Sao Paulo, SP, Brazil</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Ophthalmology, UNIFESP&amp;EPM</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/eyediseases.html</url>
    <description>eye diseases</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>FDA Resources on Drugs and Devices</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of São Paulo</investigator_affiliation>
    <investigator_full_name>Rossen Mihaylov Hazarbassanov, MD, PhD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

